Victor Filadora, MS, MD, MBA

PrintE-mail
Assistant Professor
Chief, Department of Perioperative Medicine
Director, Center for Preoperative Evaluation
Medical Director, Ambulatory Surgical Center and Post Anesthesia Care Unit
Department of Anesthesiology & Pain Medicine
Associate Dean, Graduate Medical Education
Roswell Park Cancer Institute
Assistant Professor of Anesthesiology
School of Medicine and Biomedical Sciences, State University of New York at Buffalo

Profile

Areas of Expertise: 
Perioperative medicine

Research

Research Interests: 
Clinical research
Outcomes-based research in perioperative medicine

Background Information

Education and Training: 
MD - School of Medicine and Biomedical Sciences, State University of New York at Buffalo
MS - School of Medicine and Biomedical Sciences, State University of New York at Buffalo
MBA - School of Management, Executive MBA Program, State University of New York at Buffalo
Residency: 
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Board Certification: 
Anesthesiology, American Board of Anesthesiology
Diplomate, American Board of Anesthesiology
Diplomate, National Board of Medical Examiners

Publications

Publications: 
  • Butt ZM, Fazili A, Tan W, Wilding GE, Filadora V, Kim HL, Mohler JL, O'Leary KA, Guru KA. Does the presence of significant risk factors affect perioperative outcomes after robot-assisted radical cystectomy?. BJU international 2009; 104(7):986-990
  • Matsuno F, Filadora VA II, Vankouwenberg D, Tsujie M, Tsujie T, Tsai H, Seon BK. Suppression of growth of human malignant B cells by naked monoclonal antibodies that target ectoepitopes of the Ig alpha/Ig ss (CD79) component of the human B cell antigen receptor complex. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:972-973

Cancer Can't Win

More patients are being diagnosed with cancer every day.

Here at Roswell Park Cancer Institute, we must continue to do what we do best – to understand, prevent and cure cancer. Because if we don’t, cancer wins. And Cancer Can’t Win.

  • With more than 3,000 scientific, academic and medical minds – Cancer Can’t Win.
  • When we are leading an advanced genetic program and creating next generation cancer vaccines to prevent it – Cancer Can’t Win.
  • When we are starting 13 new companies to advance our discoveries and share them with the world – Cancer Can’t Win.

Learn more about why Cancer Can’t Win

close